Phospho-PTK2 (Y397) Antibody

What is the biological significance of PTK2/FAK phosphorylation at Y397?

Y397 represents the major autophosphorylation site of PTK2 (also known as FAK) and serves as the key activation step in focal adhesion kinase signaling. Upon integrin engagement with extracellular matrices, FAK is translocated to focal contact sites where it undergoes autophosphorylation at Y397. This phosphorylation creates a high-affinity binding site that recruits and activates Src kinases through a dual interaction with their SH2 and SH3 domains . The phosphorylation at Y397 is critical for mediating downstream signaling pathways and promotes interactions with multiple proteins including SRC, BMX, PIK3R1, and SHC1 . Functionally, this activation step regulates cell migration, invasion, proliferation, and plays important roles in cancer progression .

How does PTK2 Y397 phosphorylation differ from other phosphorylation sites on the protein?

PTK2/FAK contains multiple phosphorylation sites including tyrosines (Y397, Y576, Y577, Y861, Y925) and serines (S722, S910), each with distinct regulatory functions:

Notably, Y397 phosphorylation occurs first and is essential for subsequent phosphorylation events. Unlike Y861 and Y925, which can be phosphorylated by FER even in non-adherent cells, Y397 phosphorylation typically occurs only when cells are adherent . This makes Y397 phosphorylation a particularly valuable marker for studying integrin-dependent FAK activation.

What are typical baseline levels of PTK2 Y397 phosphorylation in different cell types?

PTK2 Y397 phosphorylation levels vary significantly across cell types, with notable expression patterns observed in:

• B and T-lymphocytes show detectable baseline expression

• Epithelial cells exhibit constitutive expression patterns

• Lung fibroblasts demonstrate quantifiable baseline levels of both total and phosphorylated protein

• Cancer cell lines, particularly those derived from gastric carcinomas and NSCLC, often show elevated baseline phosphorylation compared to non-transformed cells

Researchers should establish baseline levels specific to their experimental cell types before assessing changes due to treatments or stimuli. Western blot quantification normalized to total PTK2 is the standard approach for establishing these baseline ratios.

What are the optimal sample preparation conditions to preserve PTK2 Y397 phosphorylation status?

Preserving phosphorylation status during sample preparation is critical for accurate analysis of PTK2 Y397 phosphorylation:

• Use phosphatase inhibitor cocktails containing sodium orthovanadate (1-2 mM) and sodium fluoride (5-10 mM) in all buffers

• Process samples rapidly at 4°C to minimize dephosphorylation

• For cell lysates, use RIPA buffer supplemented with both phosphatase and protease inhibitors

• For tissue samples, snap-freeze in liquid nitrogen immediately after collection

• When performing immunocytochemistry, fix cells with 4% paraformaldehyde to better preserve phospho-epitopes compared to methanol fixation

• For proximity ligation assays, follow specialized buffer conditions: PBS without Mg²⁺ and Ca²⁺, 150 mM NaCl, pH 7.4 with 0.02% sodium azide

Note that phosphorylation can be rapidly lost during sample manipulation, so validation of preservation methods through time course experiments is recommended for each experimental system.

How can I effectively quantify relative changes in PTK2 Y397 phosphorylation across experimental conditions?

For accurate quantification of PTK2 Y397 phosphorylation across conditions:

• Western blot analysis:

  • Always probe for both phospho-Y397 and total PTK2 on separate blots or after stripping

  • Calculate phospho-to-total PTK2 ratios to normalize for loading and expression differences

  • Use densitometry software with background subtraction

  • Include gradient standards to ensure measurements fall within the linear detection range

• Immunofluorescence quantification:

  • Employ automated image analysis software to measure signal intensity at focal adhesions

  • Normalize phospho-signal to total PTK2 signal in dual-stained samples

  • Analyze at least 50-100 cells per condition across 3+ biological replicates

• Proximity ligation assay:

  • Each red dot represents a single phosphorylated protein molecule

  • Use specialized software (e.g., BlobFinder from Uppsala University) to quantify dots per cell

  • Compare dot density across treatment conditions

• Statistical analysis:

  • Apply appropriate statistical tests (ANOVA followed by post-hoc tests for multiple comparisons)

  • Report both fold-change and statistical significance

This multi-method approach minimizes biases associated with any single method and provides stronger evidence for genuine biological changes.

What controls are essential when working with Phospho-PTK2 (Y397) antibodies?

When designing experiments with Phospho-PTK2 (Y397) antibodies, include these critical controls:

• Positive controls:

  • Cell lines treated with EGF or pervanadate (1-2 mM) to induce phosphorylation

  • Raji or Jurkat cells stimulated with anti-CD3e antibodies (10 μg/mL for 15 minutes)

• Negative controls:

  • Antigen competition: Pre-incubate antibody with phospho-peptide to verify specificity

  • Phosphatase treatment: Treat duplicate samples with lambda phosphatase to remove phosphorylation

  • Y397F mutant: Use cells expressing the Y397F mutation as a negative control for phosphorylation

• Validation controls:

  • Use multiple antibody clones targeting the same phospho-epitope

  • Include knockdown/knockout cells to verify signal specificity

  • For clinical samples, include serial sections with and without primary antibody

• Normalization controls:

  • Always probe for total PTK2 to normalize phosphorylation signals

  • Include housekeeping proteins (β-actin, GAPDH) as loading controls

  • For immunofluorescence, use F-actin or paxillin staining to identify focal adhesions

Proper controls ensure that observed changes in phosphorylation are genuine biological effects rather than technical artifacts.

Why might Western blot detection of Phospho-PTK2 (Y397) show inconsistent results?

Several factors can contribute to inconsistent Phospho-PTK2 (Y397) Western blot results:

• Phosphorylation instability:

  • Rapid dephosphorylation during sample preparation due to insufficient or degraded phosphatase inhibitors

  • Delayed sample processing allowing phosphatase activity

  • Repeated freeze-thaw cycles degrading phospho-epitopes

• Antibody-specific issues:

  • Batch-to-batch variability in antibody performance

  • Suboptimal primary antibody dilution (recommended range: 1:2000-1:4000)

  • Inadequate blocking leading to high background

  • Cross-reactivity with other phosphorylated proteins

• Sample preparation concerns:

  • Cell lysis conditions disrupt phosphorylation status

  • Overloading protein causing signal saturation

  • Cell density variations affecting baseline phosphorylation levels

• Technical variables:

  • Inconsistent transfer efficiency during blotting

  • Different ECL reagent sensitivity across experiments

  • Variable exposure times affecting signal intensity

To improve consistency, standardize all aspects of the protocol including sample preparation timing, lysis buffer composition, protein loading amount, transfer conditions, antibody dilutions, and detection parameters across experiments.

How can I distinguish between specific Phospho-PTK2 (Y397) signal and background or non-specific binding?

To ensure signal specificity when working with Phospho-PTK2 (Y397) antibodies:

• Validation approaches:

  • Peptide competition assay: Pre-incubate antibody with phosphorylated peptide vs. non-phosphorylated peptide

  • Compare signal with multiple antibody clones targeting the same epitope

  • Verify signal disappearance after PTK2 knockdown/knockout

  • Confirm signal enhancement after treatments known to increase Y397 phosphorylation (e.g., EGF, pervanadate)

• Signal characteristics:

  • Specific Phospho-PTK2 (Y397) signal should appear at 119-125 kDa (exact size depends on the cell type and phosphorylation status)

  • In immunofluorescence, specific signal localizes primarily at focal adhesions rather than diffuse cytoplasmic staining

  • In proximity ligation assays, specific signals appear as distinct dots rather than diffuse background

• Technical approaches:

  • Use gradient gels to better resolve the target protein band

  • Optimize blocking conditions (5% BSA is often superior to milk for phospho-epitopes)

  • Increase washing stringency with higher detergent concentration

  • For monoclonal antibodies, verify the clone's validation data

Proper controls and optimized protocols significantly enhance signal specificity and reduce ambiguity in interpretation.

How does PTK2 Y397 phosphorylation contribute to cancer progression and therapy resistance?

PTK2 Y397 phosphorylation plays multiple roles in cancer progression and therapy resistance:

• Cancer progression mechanisms:

  • Promotes cell migration and invasion capabilities essential for metastasis

  • Enhances cancer cell proliferation through downstream AKT signaling

  • Contributes to anchorage-independent growth, allowing tumor cells to survive without ECM attachment

  • Facilitates angiogenesis through regulation of endothelial cell function

• Clinical significance:

  • Higher levels of pY397 FAK correlate with increased recurrence rates in gastric cancer patients

  • Serves as an independent predictor of gastric cancer recurrence after surgery

  • Associated with poor 5-year recurrence-free survival in gastric carcinoma patients

• Therapy resistance mechanisms:

  • Confers resistance to EGFR-TKI therapy in non-small cell lung cancer through:

    • Hyperphosphorylation of PTK2 at Y397 in resistant cell lines (PC-9/PEM)

    • Constitutive activation of Akt signaling independent of EGFR inhibition

    • Maintenance of cell survival pathways despite EGFR blockade

• Therapeutic targeting:

  • Combination of PTK2 inhibitors (e.g., defactinib) with EGFR-TKIs (e.g., osimertinib) overcomes resistance

  • PTK2 inhibition sensitizes cancer cells to DNA-damaging agents like etoposide and cisplatin

  • Targeting PTK2 Y397 phosphorylation impairs cancer cell migration, invasion, and proliferation

These findings highlight PTK2 Y397 phosphorylation as both a prognostic marker and a therapeutic target in various cancers.

What experimental approaches are most suitable for studying dynamic changes in PTK2 Y397 phosphorylation?

For capturing dynamic changes in PTK2 Y397 phosphorylation, researchers should consider these approaches:

• Real-time imaging techniques:

  • Live-cell FRET-based biosensors incorporating PTK2 and phospho-specific binding domains

  • Proximity ligation assays for fixed time-point analyses with single-molecule resolution

  • Fluorescence recovery after photobleaching (FRAP) with GFP-tagged PTK2 to monitor turnover rates at focal adhesions

• Biochemical time-course analyses:

  • Rapid cell lysis at closely spaced time points (seconds to minutes)

  • Phospho-specific Western blotting with quantification of phospho-to-total PTK2 ratios

  • ELISA-based phosphorylation detection for higher throughput analyses

• Spatial distribution analysis:

  • Super-resolution microscopy (STORM, PALM) to visualize phospho-PTK2 localization at nanometer resolution

  • Dual-color immunofluorescence comparing phosphorylated vs. total PTK2 distribution

  • Subcellular fractionation followed by Western blotting to track phospho-PTK2 movement between compartments

• Functional correlation approaches:

  • Simultaneous tracking of phospho-PTK2 levels and focal adhesion dynamics

  • Correlation of phosphorylation with downstream signaling activities (e.g., SRC activation, AKT phosphorylation)

  • Real-time monitoring of cell migration rates in relation to phosphorylation changes

These methodologies, when applied in combination, provide comprehensive insights into both the kinetics and spatial dynamics of PTK2 Y397 phosphorylation in response to various stimuli.

How do different experimental conditions affect PTK2 Y397 phosphorylation detection?

Various experimental conditions can significantly impact PTK2 Y397 phosphorylation detection:

• Cell culture variables:

  • Cell density: Confluent cultures often show different baseline phosphorylation than sparse cultures

  • Substrate rigidity: Stiffer substrates generally increase phosphorylation at Y397

  • Serum starvation: Typically reduces baseline phosphorylation, making stimulation effects more pronounced

  • ECM composition: Different matrix proteins (fibronectin vs. collagen) induce varying levels of phosphorylation

• Treatment considerations:

  • EGF stimulation: Rapidly increases Y397 phosphorylation (peak at 15-30 minutes)

  • Pervanadate exposure: Strongly enhances phosphorylation by inhibiting phosphatases (1-2 mM for 30 minutes)

  • Integrin activation: Antibody-mediated clustering increases Y397 phosphorylation

  • Microtubule dynamics: Disruption leads to dephosphorylation at Y397

• Technical detection factors:

  • Antibody clone selection: Different clones exhibit varying sensitivity to the phospho-epitope

  • Sample preparation: For immunofluorescence, paraformaldehyde fixation better preserves phospho-epitopes than methanol

  • Blocking agents: BSA is generally superior to milk for phospho-epitope detection

  • Buffer composition: Phosphatase inhibitor cocktails are essential in all steps

• Validation approaches:

  • Positive controls: Include EGF-treated samples (293 cells) or anti-CD3e-stimulated Jurkat cells

  • Negative controls: Use lambda phosphatase-treated samples or antigen competition

Researchers should systematically optimize these conditions for their specific experimental system to ensure reliable and reproducible phosphorylation detection.

How might single-cell analysis methods advance our understanding of PTK2 Y397 phosphorylation heterogeneity?

Single-cell analysis provides valuable insights into PTK2 Y397 phosphorylation heterogeneity that are masked in population-level studies:

• Current methodological approaches:

  • Single-cell Western blotting techniques can detect phospho-PTK2 in individual cells

  • Mass cytometry (CyTOF) with phospho-specific antibodies enables multi-parameter analysis

  • Proximity ligation assays provide quantitative single-molecule detection at the individual cell level

  • Microfluidic platforms allow temporal analysis of phosphorylation in single cells

• Research applications:

  • Analyzing phosphorylation heterogeneity within tumor cell populations

  • Correlating phospho-PTK2 levels with cell migration speed and directionality at the single-cell level

  • Identifying rare cell subpopulations with distinct phosphorylation patterns

  • Tracking phosphorylation dynamics through cell cycle progression

• Advantages over population methods:

  • Reveals subpopulations that would be averaged out in bulk analysis

  • Enables correlation of phosphorylation with other cellular parameters in the same cell

  • Provides insights into cell-to-cell variability in response to treatments

  • Allows tracking of rare cellular events

• Technical considerations:

  • Antibody specificity becomes even more critical at the single-cell level

  • Signal amplification methods may be needed for low-abundance detection

  • Appropriate normalization and quantification strategies must be developed

  • Computational tools for analyzing single-cell phosphorylation data are essential

This emerging direction will likely provide unprecedented insights into how phosphorylation heterogeneity contributes to cellular function and disease processes.

What is the relationship between PTK2 Y397 phosphorylation and resistance to targeted therapies?

PTK2 Y397 phosphorylation has emerged as a key mechanism of resistance to multiple targeted therapies:

• EGFR-TKI resistance in NSCLC:

  • Hyperphosphorylation of PTK2 at Y397 occurs in EGFR-TKI-resistant cell lines

  • PTK2 activation maintains Akt signaling despite EGFR inhibition

  • Combination of PTK2 inhibitor (defactinib) and EGFR-TKI (osimertinib) overcomes resistance

  • PTK2 inhibition enhances EGFR-TKI efficacy in both in vitro and in vivo models

• Chemotherapy resistance mechanisms:

  • PTK2 Y397 phosphorylation confers resistance to DNA-damaging agents

  • PTK2 inhibition significantly enhances sensitivity to etoposide and cisplatin

  • PTK2 knockdown decreases colony formation in HCT116 cells treated with chemotherapeutics

• Resistance biomarkers:

  • Y397 phosphorylation levels correlate with therapy response in patient samples

  • Monitoring phosphorylation changes during treatment may predict resistance development

  • PTK2 inhibitors show synergistic effects with various targeted therapies in resistant cell lines

• Targeting approaches:

  • Small molecule inhibitors of PTK2 kinase activity (PF-573228)

  • Disruption of Y397 phosphorylation through SRC inhibition

  • Combination strategies targeting both PTK2 and primary oncogenic drivers

  • Expression of dominant-negative PTK2 mutants (Y397F) to impair cell survival pathways

These findings suggest that PTK2 Y397 phosphorylation serves as both a resistance mechanism and a therapeutic target that could enhance the efficacy of existing cancer treatments.

How does the subcellular localization of phosphorylated PTK2 Y397 influence its signaling outcomes?

The subcellular localization of phosphorylated PTK2 Y397 critically determines its downstream signaling consequences:

• Focal adhesion localization:

  • Classical site for PTK2 Y397 phosphorylation following integrin engagement

  • Promotes local activation of SRC family kinases

  • Facilitates assembly of adhesion complexes and maturation of focal adhesions

  • Regulates cell-matrix adhesion dynamics and migration

• Nuclear localization:

  • Phosphorylated PTK2 can translocate to the nucleus through mechanisms distinct from PYK2

  • PKC-mediated phosphorylation of FAK on S722 promotes nuclear localization

  • Nuclear phospho-PTK2 may regulate gene expression and cell cycle progression

  • In cancer cells, nuclear phospho-PTK2 correlates with aggressive phenotypes

• Cytoplasmic signaling complexes:

  • Phospho-PTK2 forms signaling complexes away from focal adhesions

  • Associates with endosomes and other vesicular compartments

  • May participate in different signaling pathways depending on complex composition

  • Influences cellular responses to growth factors and cytokines

• Experimental approaches to study localization:

  • Subcellular fractionation followed by Western blotting for phospho-PTK2

  • Confocal microscopy with co-localization analysis of phospho-PTK2 and compartment markers

  • FRET-based reporters to detect phosphorylation in different cellular compartments

  • Live-cell imaging to track phospho-PTK2 translocation dynamics

Understanding the relationship between subcellular localization and signaling outcomes provides important insights into how PTK2 orchestrates diverse cellular processes in both normal and pathological contexts.